STAAR Surgical (STAA) Expected to Release Earnings on Wednesday

STAAR Surgical (NASDAQ:STAA) is projected to post its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect STAAR Surgical to post earnings of $0.0503 per share and revenue of $78.73 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 5:30 PM ET.

STAAR Surgical (NASDAQ:STAA) last posted its earnings results on Wednesday, August 12th. The medical instruments supplier reported $0.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $0.17. The business had revenue of $93.53 million during the quarter, compared to analyst estimates of $90.60 million. The firm’s revenue was up 111.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.34) earnings per share. On average, analysts expect STAAR Surgical to post $0.39 EPS for the current fiscal year and $0.58 EPS for the next fiscal year.

STAAR Surgical Stock Up 4.0%

NASDAQ STAA opened at $24.16 on Wednesday. The stock’s 50-day moving average is $22.38 and its 200-day moving average is $23.51. STAAR Surgical has a one year low of $15.59 and a one year high of $35.87.

STAAR Surgical declared that its Board of Directors has initiated a stock buyback plan on Thursday, September 24th that allows the company to repurchase $50 million in shares. This repurchase authorization allows the medical instruments supplier to repurchase up to 5.2% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Analysts Set New Price Targets

A number of analysts recently issued reports on STAA shares. UBS Group set a $28.00 target price on STAAR Surgical in a research note on Monday, August 17th. Weiss Ratings raised shares of STAAR Surgical from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Thursday, August 13th. William Blair set a $33.00 price target on shares of STAAR Surgical in a report on Thursday, August 13th. Wedbush reduced their price target on shares of STAAR Surgical from $40.00 to $37.00 and set an “outperform” rating for the company in a report on Thursday, August 13th. Finally, Stifel Nicolaus raised shares of STAAR Surgical from a “hold” rating to a “buy” rating and increased their price objective for the stock from $28.00 to $31.00 in a research report on Tuesday, September 29th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $28.45.

STAAR Surgical Company Profile

STAAR Surgical is a medical device company focused on ophthalmic surgery and vision correction. The company develops, manufactures and markets implantable lenses and related products designed to reduce or eliminate dependence on glasses or contact lenses.

Its principal product line is the EVO Visian Implantable Collamer Lens (ICL), a lens implanted inside the eye to correct myopia, with or without astigmatism. Unlike procedures that remove corneal tissue, ICL surgery preserves the eye’s natural lens and is designed to be removable.